Previous 10 | Next 10 |
Agenus (NASDAQ:AGEN) stock rose May 10 after the company's Q1 results beat analysts' estimates. The company said it began cost containment measures with expected reductions in operating expenses in coming quarters. Q1 total revenue grew +121.36% Y/Y to $25.94M. "In the current challengin...
Agenus press release (NASDAQ:AGEN): Q1 GAAP EPS of -$0.19 beats by $0.11. Revenue of $25.94M (+121.3% Y/Y) beats by $14.14M. Agenus received $5M milestone payment with up to $570 million in future potential option fees and milestones. Cash and short-term investment balance of $263 million as ...
Botensilimab data to be presented and Phase 2 trials to launch. AGEN1571 (ILT2) clinical trials to commence and data presented at AACR. AGEN2373 progressing in the clinic and Gilead milestone payment received. LEXINGTON, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Agenus Inc...
Agenus (NASDAQ:AGEN) is scheduled to announce Q1 earnings results on Tuesday, May 10th, before market open. The consensus EPS Estimate is -$0.29 (-7.4% Y/Y) and the consensus Revenue Estimate is $11.8M (+0.7% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward revisions and 1 downw...
LEXINGTON, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced it will release its first quart...
Shares of the small-cap cancer companies Adaptimmune Therapeutics (NASDAQ: ADAP) , Agenus (NASDAQ: AGEN) , and Sorrento Therapeutics (NASDAQ: SRNE) all rose by more than 5% during Tuesday's trading session. Adaptimmune, Agenus, and Sorrento appear to be getting a muc...
Agenus has proven its clinical capabilities over and over again. Despite its successful collaborations, Agenus has never caught on with investors and is now trading near its all time lows. Agenus' recent Q4, 2021 earnings call shows that its curse of poor performance is alive and ...
First data presentation on AGEN1571 shows strong adaptive and innate immune responses Preclinical data indicate superior performance to the only clinical-stage competitor Monotherapy activity and broad combination potential Investigational New Drug (IND) application cleared;...
LEXINGTON, Mass., April 05, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate immune response to cancers and infections, today announced receipt of a $5M clinical milestone payment for AGEN2373 (co...
This article focuses on the major influences towards a biotech company's share price, rather than their value or opportunity. These catalysts will be important to consider when timing your entry and exit points. This article will be the last that focuses on evaluating individual h...
News, Short Squeeze, Breakout and More Instantly...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its second quarter 2024 financial results before the market opens on Thursday, August 8, 2024. Agenus executives will host a co...
A look at the top 10 most actives in the United States Onconetix Inc. (ONCO) rose 46.5% to $0.2183 on volume of 404,016,812 shares NVIDIA Corporation (NVDA) rose 2.6% to $121.09 on volume of 317,123,916 shares PROSHARES TRUST (SQQQ) rose 1.5% to $8.23 on volume of 207,449,647 shares Max...
2024-07-18 12:11:22 ET Agenus Inc (NASDAQ: AGEN) faced a dramatic decline in its stock price on Thursday, plummeting more than 50%, following the US Food and Drug Administration (FDA’s) decision to advise against pursuing accelerated approval for its BOT/BAL colorectal cance...